PALI

Business Context and Reporting Period

Company: Neuralstem, Inc. (Note: Input metadata referenced "Palisade Bio," but the filing text identifies the registrant as Neuralstem, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Neuralstem is a biopharmaceutical company focused on developing treatments for central nervous system (CNS) diseases using human neural stem cells and small molecule compounds. The company is in the pre-clinical and clinical development stages with no commercial products currently on the market.

Key Financial Metrics

Note: 2010 revenue consisted entirely of federal grants totaling $733,438 awarded under the Patient Protection and Affordable Care Act.

Material Changes vs. Prior Period

• Revenue Generation: The company recorded its first revenue in 2010 ($733,438) compared to zero in 2009, derived solely from federal grants.
• Net Loss Increase: Net loss increased by approximately 78% year-over-year, driven by a 71% increase in Research & Development (R&D) expenses and a 32% increase in General & Administrative (G&A) expenses.
• Liquidity Improvement: Cash and cash equivalents increased by 301% to $9.26 million, primarily due to the exercise of outstanding warrants and a registered direct offering of securities in June 2010.
• Non-Operating Expenses: The company incurred a significant non-operating expense of $3.2 million in 2010, largely due to a $1.9 million warrant modification expense and a $1.35 million loss on the change in fair value of warrant obligations.

Guidance, Outlook, and Risks

Clinical Progress and Outlook

• ALS Trial: The Phase I clinical trial for Amyotrophic Lateral Sclerosis (ALS) using spinal cord stem cells is ongoing. As of the filing date, 11 patients had been treated. The Safety Monitoring Board approved moving to the next cohort.
• Depression Trial: The FDA approved the Investigational New Drug (IND) application for NSI-189, a small molecule compound for Major Depressive Disorder, in December 2010. The first subject was dosed in February 2011.
• Spinal Cord Injury: An IND for chronic spinal cord injury was filed in August 2010 but was placed on clinical hold by the FDA in October 2010 pending protocol modifications.

Management Commentary

Management estimates sufficient cash to fund operations for at least 12 months from December 31, 2010, assuming the second IND (spinal cord injury) is not commenced. If the second trial begins, the monthly cash burn rate is expected to increase to approximately $1.2 million. The company anticipates needing additional capital to fund future clinical trials and operations.

Risks and Contingencies

• Capital Requirements: The company has a history of losses and relies on external financing. Failure to secure additional capital could force the delay or elimination of research programs.
• Regulatory Risk: The spinal cord injury trial is currently on clinical hold. There is no assurance that FDA approval will be granted for any product candidates.
• Legal Proceedings: Ongoing patent litigation with StemCells, Inc. regarding stem cell culture compositions remains in its initial stages with an uncertain outcome.
• Warrant Liability: Significant volatility in the fair value of warrant obligations classified as liabilities impacts net income.

Key Facts for Investor Verification

• Cash Runway: Verify the current cash balance against the stated monthly burn rate of ~$900,000 to assess immediate liquidity needs.
• Spinal Cord Injury IND Status: Confirm the current status of the FDA clinical hold on the spinal cord injury trial and any subsequent approvals.
• Warrant Liability: Review the fair value of remaining warrant obligations, as changes in stock price directly impact reported net loss.
• Grant Funding: Verify the receipt of the remaining balance of the $733,438 federal grant awarded in November 2010.
• Legal Settlement: Confirm the terms and financial impact of the settlement reached with ReNeuron, Ltd. in January 2011.